985 results on '"Parmiani, Giorgio"'
Search Results
152. Lack of anti-TSTA antibodies in mice immunized with a methylcholanthrene-induced fibrosarcoma
153. Genetic control of responsiveness to the tumor-associated transplantation antigen of a chemically induced murine fibrosarcoma
154. Anti-H-2 alloantibodies elicited by syngeneic immunizations with a chemically induced fibrosarcoma
155. Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells
156. Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma
157. Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells
158. Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK)
159. Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin
160. Generation of TSTA diversity: Looking for testable hypotheses
161. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes
162. Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
163. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
164. Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy
165. A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.
166. Consensus nomenclature for CD8+T cell phenotypes in cancer
167. Gene Therapy in Melanoma
168. Melanoma: The Milan Melanoma Cell Lines
169. A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma
170. Peptide-based vaccines for cancer therapy
171. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer
172. “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013
173. Awareness and understanding of cancer immunotherapy in Europe
174. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
175. Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4
176. Reconstitution of hTERT expression allows successful immortalization of short-lived primary cultures of colorectal carcinoma: A new tool for the efficient generation of colorectal carcinoma cell lines
177. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
178. Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
179. Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP).
180. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).
181. Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).
182. Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
183. Awareness and understanding of cancer immunotherapy in Europe.
184. Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules
185. Follow-Up of Melanoma: A Survey of Italian Hospitals
186. Surgical Treatment of Melanoma: A Survey of Italian Hospitals
187. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes
188. Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
189. Validation of Stereotyped Immunoglobulin Heavy Chain CDR3 Sequences As Candidate Antigens for Immunotherapy of CLL
190. Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes
191. Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.
192. The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.
193. Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
194. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes
195. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy
196. Autologous Versus Allogeneic Cell-Based Vaccines?
197. Pre-Clinical and Clinical Aspects of Peptide-based Vaccine Against Human Solid Tumors
198. Tumor antigens recognized by T cells and antibodies
199. POTENTIATION OF ADOPTIVE IMMUNOTHERAPY BY cis-DIAMMINEDICHLOROPLATINUM(II), BUT NOT BY DOXORUBICIN, ON A DISSEMINATED MOUSE LYMPHOMA AND ITS ASSOCIATION WITH REDUCTION OF TUMOR BURDEN
200. LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.